Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and tolerability of neoadjuvant tislelizumab, gemcitabine, cisplatin and S-1 (TisGCS) in patients with resectable high-risk iCCA.
Phase:
PHASE2
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborators:
Chi Mei Medical Hospital Kaohsiung Veterans General Hospital.
Treatments:
Cisplatin Gemcitabine S 1 (combination) tislelizumab